NASDAQ:AMRN - Amarin Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $16.68 -0.23 (-1.36 %) (As of 12/10/2018 04:00 PM ET)Previous Close$16.91Today's Range$16.02 - $17.1052-Week Range$2.35 - $23.33Volume5.35 million shsAverage Volume6.78 million shsMarket Capitalization$5.46 billionP/E Ratio-66.72Dividend YieldN/ABeta0.66 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Amarin Corporation plc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States. The company's lead product is Vascepa, a prescription-only omega-3 fatty acid capsule, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It is also involved in developing Vascepa for the treatment of patients with high triglyceride levels who are also on statin therapy for elevated low-density lipoprotein cholesterol levels. Amarin Corporation plc sells its products principally to wholesalers and specialty pharmacy providers through direct sales force. It has collaboration with Mochida Pharmaceutical Co., Ltd. for the development of EPA-Based drug products and indications. The company was formerly known as Ethical Holdings plc and changed its name to Amarin Corporation plc in 1999. Amarin Corporation plc was founded in 1989 and is based in Dublin, Ireland. Receive AMRN News and Ratings via Email Sign-up to receive the latest news and ratings for AMRN and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AMRN Previous Symbol CUSIPN/A Webwww.amarincorp.com Phone353-1669-9020 Debt Debt-to-Equity RatioN/A Current Ratio1.33 Quick Ratio1.05 Price-To-Earnings Trailing P/E Ratio-66.72 Forward P/E Ratio-46.33 P/E GrowthN/A Sales & Book Value Annual Sales$181.10 million Price / Sales26.92 Cash FlowN/A Price / Cash FlowN/A Book Value($0.33) per share Price / Book-50.55 Profitability EPS (Most Recent Fiscal Year)($0.25) Net Income$-67,860,000.00 Net Margins-51.15% Return on EquityN/A Return on Assets-53.17% Miscellaneous Employees241 Outstanding Shares292,320,000Market Cap$5.46 billion OptionableOptionable Amarin (NASDAQ:AMRN) Frequently Asked Questions What is Amarin's stock symbol? Amarin trades on the NASDAQ under the ticker symbol "AMRN." How were Amarin's earnings last quarter? Amarin Co. plc (NASDAQ:AMRN) issued its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.01. The biopharmaceutical company had revenue of $55 million for the quarter, compared to analyst estimates of $60.63 million. The company's quarterly revenue was up 16.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.04) earnings per share. View Amarin's Earnings History. When is Amarin's next earnings date? Amarin is scheduled to release their next quarterly earnings announcement on Tuesday, February 26th 2019. View Earnings Estimates for Amarin. What price target have analysts set for AMRN? 5 brokers have issued 12 month target prices for Amarin's stock. Their predictions range from $15.00 to $51.00. On average, they anticipate Amarin's stock price to reach $31.80 in the next twelve months. This suggests a possible upside of 90.6% from the stock's current price. View Analyst Price Targets for Amarin. What is the consensus analysts' recommendation for Amarin? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amarin in the last year. There are currently 1 sell rating, 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amarin. What are Wall Street analysts saying about Amarin stock? Here are some recent quotes from research analysts about Amarin stock: 1. Cantor Fitzgerald analysts commented, "We think the peak sales potential of Vascepa is underappreciated. Therefore, upward earnings revisions to levels not reflected in FactSet consensus expectations should drive AMRN shares higher. Valuation Summary We continue to use a blend of DCF and multiples (EV/EBITDA) analysis to get to our 12-month price target of $35." (12/7/2018) 2. HC Wainwright analysts commented, "We believe that beyond the topline of 25% reduction of MACE score, the robustness of the data is highlighted by the consistency across pre-specified analyses. A key secondary composite, namely 3-point MACE score (cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke), which assesses the major CV events (and reflects the most important clinical relevance), showed an even higher reduction of risks at 26% compared to placebo. The clinical benefits as measured by the primary endpoint of MACE score and the key secondary 3-point MACE score are observed across subgroups (statistically significant in the vast majority of the subgroups), which speaks to the validity and robustness of the data." (11/12/2018) 3. According to Zacks Investment Research, "Amarin Corporation plc is a global pharmaceutical group which develops innovative pharmaceutical products across a range of therapeutic areas utilizing its proprietary advanced oral and transdermal drug delivery technologies. " (8/8/2018) Has Amarin been receiving favorable news coverage? Media headlines about AMRN stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research firm rates the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amarin earned a news impact score of 1.9 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 7.0 out of 10, meaning that recent media coverage is likely to have an effect on the company's share price in the near term. Are investors shorting Amarin? Amarin saw a drop in short interest in November. As of November 15th, there was short interest totalling 11,354,568 shares, a drop of 35.1% from the October 31st total of 17,500,650 shares. Based on an average daily volume of 17,939,623 shares, the days-to-cover ratio is presently 0.6 days. Currently, 3.9% of the company's shares are short sold. View Amarin's Current Options Chain. Who are some of Amarin's key competitors? Some companies that are related to Amarin include Teva Pharmaceutical Industries (TEVA), UCB (UCBJF), BioMarin Pharmaceutical (BMRN), Mylan (MYL), Ono Pharmaceutical (OPHLF), Merck KGaA (MKGAF), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Jazz Pharmaceuticals (JAZZ), Bausch Health Companies (BHC), Beigene (BGNE), Perrigo (PRGO), Sarepta Therapeutics (SRPT), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS). Who are Amarin's key executives? Amarin's management team includes the folowing people: Mr. John F. Thero, Pres, CEO & Director (Age 57)Mr. Michael W. Kalb, CFO, Sr. VP & Assistant Sec. (Age 47)Dr. Steven B. Ketchum, Pres of R&D, Sr. VP and Chief Scientific Officer (Age 53)Mr. Joseph T. Kennedy, Chief Compliance Officer, Exec. VP of Strategic Initiatives, Gen. Counsel and Sec. (Age 50)Ms. Elisabeth Schwartz, Sr. Director of Investor Relations Who are Amarin's major shareholders? Amarin's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Baker BROS. Advisors LP (11.65%), Oracle Investment Management Inc. (2.00%), Sofinnova Ventures Inc (1.78%), Clearbridge Investments LLC (1.27%), BlackRock Inc. (1.16%) and Morgan Stanley (1.10%). Company insiders that own Amarin stock include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Michael Wayne Kalb and Steven B Ketchum. View Institutional Ownership Trends for Amarin. Which major investors are selling Amarin stock? AMRN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Stonepine Capital Management LLC, Stonepine Capital Management LLC, Sofinnova Ventures Inc, Morgan Stanley, Opaleye Management Inc., Wells Fargo & Company MN and Hsbc Holdings PLC. Company insiders that have sold Amarin company stock in the last year include John F Thero, Joseph S Zakrzewski, Joseph T Kennedy, Michael Wayne Kalb and Steven B Ketchum. View Insider Buying and Selling for Amarin. Which major investors are buying Amarin stock? AMRN stock was acquired by a variety of institutional investors in the last quarter, including Baker BROS. Advisors LP, Clearbridge Investments LLC, Point72 Asset Management L.P., EULAV Asset Management, Rubric Capital Management LP, C WorldWide Group Holding A S, Perceptive Advisors LLC and Oracle Investment Management Inc.. View Insider Buying and Selling for Amarin. How do I buy shares of Amarin? Shares of AMRN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Amarin's stock price today? One share of AMRN stock can currently be purchased for approximately $16.68. How big of a company is Amarin? Amarin has a market capitalization of $5.46 billion and generates $181.10 million in revenue each year. The biopharmaceutical company earns $-67,860,000.00 in net income (profit) each year or ($0.25) on an earnings per share basis. Amarin employs 241 workers across the globe. What is Amarin's official website? The official website for Amarin is http://www.amarincorp.com. How can I contact Amarin? Amarin's mailing address is 2 Pembroke House Upper Pembroke Street 28-32, Dublin L2, Dublin 2. The biopharmaceutical company can be reached via phone at 353-1669-9020 or via email at [email protected] MarketBeat Community Rating for Amarin (NASDAQ AMRN)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 577 (Vote Outperform)Underperform Votes: 349 (Vote Underperform)Total Votes: 926MarketBeat's community ratings are surveys of what our community members think about Amarin and other stocks. Vote "Outperform" if you believe AMRN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRN will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/10/2018 by MarketBeat.com StaffFeatured Article: How much can an individual set aside as a catch-up contribution?